Showing results (331-340 of 4,238) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|February 15, 2019
The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancerEmanuela Brunetto, Lucia De Monte, Gianpaolo Balzano, et al.Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.Journal for Immunotherapy of Cancer|October 27, 2022
Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor typesJake G Maule, Lani K Clinton, Ryon P Graf, et al.Journal for Immunotherapy of Cancer|October 28, 2022
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradationGuoliang Deng, Lisha Zhou, Binglin Wang, et al.Journal for Immunotherapy of Cancer|October 17, 2022
Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilizationQi Zhang, Bingqiu Xiu, Liyi Zhang, et al.Journal for Immunotherapy of Cancer|October 17, 2022
Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumorsAshley R Hoover, Saghar Kaabinejadian, Jason R Krawic, et al.Journal for Immunotherapy of Cancer|June 13, 2025
Inhibiting CMTM4 reverses the immunosuppressive function of myeloid-derived suppressor cells and augments immunotherapy response in cervical cancerJianyi Ding, Haoran Hu, Yashi Zhu, et al.Journal for Immunotherapy of Cancer|June 11, 2025
IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinomaWenyi Yang, Zhaoyang Guo, Houyu Ju, et al.Journal for Immunotherapy of Cancer|June 13, 2025
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysisDavid Andreu-Sanz, Lisa Gregor, Emanuele Carlini, et al.Journal for Immunotherapy of Cancer|June 8, 2025
Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancerXin Guo, Huolun Feng, Zhihui Xi, et al.Pageof 424